Posted on 1/1/20
Acorda Therapeutics Completes Exchange of $276 Million of its 1.75% Convertible Senior Notes
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced it has successfully completed its previously announced private exchange of $276 million aggregate principal amount of its 1.75% . . .
Posted on 1/1/20
Cellular Biomedicine Group Announces Engagement of Independent Advisors by Special Committee
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) announced that the special committee of its board of directors, composed of Alan Au, Edward Schafer, Terry A. Belmont and . . .
Posted on 1/1/20
Axsome Therapeutics Closes $200M Public Offering of Common Stock
NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous . . .
Posted on 1/1/20
Abeona Closes $103.5M Underwritten Public Offering
NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the . . .
Posted on 1/1/20
Starton Therapeutics: Announcing Name Change for ChemioCare
NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc., a biotechnology company focused on transforming standard of care therapeutics, today announced it has changed . . .
Posted on 1/1/20
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders
MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to . . .
Posted on 1/1/20
Outlook Therapeutics Announces Completion of Warrant Restructuring
CRANBURY, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab?for use . . .
Posted on 12/24/19
These Were the 10 Best Healthcare Stocks of 2019
Biotech, hands down, wins the race for out-performance in the healthcare sector. Delivering new, valuable medicines has proven to be a winning strategy, even if the . . .
Posted on 12/24/19
Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma
Summary Athenex tumbled on mixed data. Boston Scientific received an approval, DARE an IND. Conformis Biosciences got an FDA warning. Looking for more stock ideas like . . .
Posted on 12/24/19
Bioasis Completes Bridge Financing Transaction
GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain . . .
Posted on 12/23/19
Avalon GloboCare Partners with China Cell Valley
FREEHOLD, N.J., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has . . .
Posted on 12/23/19
Hoth Therapeutics Issues 2019 Shareholder Letter
Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and . . .
Posted on 12/23/19
Acorda Therapeutics Announces Private Exchange of $276 Million of Its 1.75% Convertible Senior Notes
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into agreements with a limited number of institutional investors who are holders of . . .
Posted on 12/23/19
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition
Bristol-Myers Squibb (NYSE:BMY) closed on its acquisition of Celgene in November. The big drugmaker announced plans to buy Celgene earlier this year for $74 billion. That . . .
Posted on 12/23/19
Better Buy: Amgen vs. Johnson & Johnson
Amgen (NASDAQ:AMGN) and Johnson & Johnson (NYSE:JNJ) have quite a few things in common. They both rank among the most attractive healthcare dividend stocks. Both companies . . .
Posted on 12/20/19
Abeona Therapeutics Announces Public Offering of Common Stock
NEW YORK and CLEVELAND, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that . . .
Posted on 12/20/19
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (Nasdaq: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous . . .
Posted on 12/20/19
Axsome Therapeutics Prices Public Offering of $174M of Shares of Common Stock
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (Nasdaq: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous . . .
Posted on 12/20/19
CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals
VANCOUVER, Washington and NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), and Vyera Pharmaceuticals, LLC, today announced that they have entered into a . . .
Posted on 12/20/19
Johnson & Johnson To Acquire Remainder Of Verb Surgical
On the heels of its successful collaboration with Alphabet's Verily Life Sciences, Johnson & Johnson (NYSE:JNJ) has agreed to acquire the remaining stake in robotics and . . .
Posted on 12/19/19
Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine
Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, . . .
Posted on 12/19/19
Turnstone Biologics Announces Global Collaboration and License Agreement with Takeda
NEW YORK--(BUSINESS WIRE)--Turnstone Biologics, a biotechnology company pioneering the development of engineered viral immunotherapies, today announced a strategic collaboration with Takeda Pharmaceutical Company Limited to develop . . .
Posted on 12/19/19
Cara Therapeutics: Recent Stock Price Plunge Was A Bit Exaggerated
Summary The company reported positive Phase II clinical results of oral KORSUVA showing a strong efficacy and safety profile compared to placebo. Management stated that the . . .
Posted on 12/19/19
How Big of a Deal Is Axsome Therapeutics' New Depression Drug?
Major single-day swings are a common occurrence in the biotech sector, as strong late-stage clinical results can send a stock surging. That's exactly what happened on . . .
Posted on 12/19/19
Teva Avoids Bankruptcy, Huge Upside
SummaryTeva refinances all-important 2021 stack.Teva's turnaround is picking up momentum.Teva is simply too cheap now.Looking for more stock ideas like this one? Get them exclusively at . . .
New York
